Iron Status, Erythropoietin, and Cancer Incidence in the General Population
European Journal of Clinical Investigation · 2026-05 · 56 (5)
DOI: 10.1111/eci.70218 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Investigation, online erschienen am 08.05.2026. Verfasst von Siem J van Alfen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. Hauptthemen laut MEDLINE: Erythropoietin, Neoplasms, Iron. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nierstichting, Hartstichting, Ministerie van Volksgezondheid, Welzijn en Sport.
Abstract (Originalsprache)
Background
Iron is essential for cellular function and cancer growth. While iron imbalance has been implicated in cancer development, epidemiological evidence remains inconsistent. Erythropoietin (EPO) may influence tumour progression. We aimed to investigate the associations between iron status, EPO levels, and cancer incidence in the general population.
Method
Data were obtained from 6109 participants (mean age 52 ± 12 years; 49% male) in the Prevention of Renal and Vascular End‐stage Disease (PREVEND) cohort. Iron biomarkers, including ferritin, transferrin saturation, soluble transferrin receptor (sTfR), hepcidin and EPO levels, were measured at baseline.
Results
Over a median 18.5 year follow‐up, 1090 participants developed cancer. Multivariable Cox regression revealed that higher EPO (HR 1.26; 95% CI 1.07–1.47; p = 0.005) was associated with increased overall cancer risk, while elevated hepcidin levels were associated with a lower risk (HR 0.88; 95% CI 0.80–0.96; p = 0.006). Higher sTfR (HR 1.35; 95% CI 1.01–1.80; p = 0.043) was suggestive for an increased risk of overall cancer. After excluding early diagnoses, the increased risk associated with higher EPO levels and decreased risk associated with higher hepcidin levels remained significant. Lower transferrin saturation was associated with increased haematological cancer risk, while higher hepcidin was associated with reduced gastrointestinal cancer risk, especially in women and those with BMI < 25 kg/m 2 . In non‐smokers, higher sTfR and EPO were associated with increased overall and kidney cancer.
Conclusion
These findings underscore the putative roles of iron metabolism and EPO in cancer, with consistently decreased risks associated with elevated hepcidin levels, particularly among women and individuals with lower BMI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Pathology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
- Department of Laboratory Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
ORCID-Profile: Siem J van Alfen, Li Luo
Förderung
- Nierstichting
- Hartstichting
- Ministerie van Volksgezondheid, Welzijn en Sport
- NIH HHS
- Universitair Medisch Centrum Groningen
- National Institutes of Health
Zitieren
APA
van Alfen, S. J., Rawee, P., Luo, L., Nolte, I. M., van der Vegt, B., Kootstra-Ros, J. E., Bakker, S. J. L., Gansevoort, R. T., Links, T. P., Zandee, W. T., & Eisenga, M. F. (2026). Iron Status, Erythropoietin, and Cancer Incidence in the General Population. European Journal of Clinical Investigation, 56(5). https://doi.org/10.1111/eci.70218
Vancouver
van Alfen SJ, Rawee P, Luo L, Nolte IM, van der Vegt B, Kootstra-Ros JE, et al. Iron Status, Erythropoietin, and Cancer Incidence in the General Population. European Journal of Clinical Investigation. 2026;56(5). doi:10.1111/eci.70218
BibTeX
@article{vanAlfen2026,
author = {van Alfen, Siem J and Rawee, Pien and Luo, Li and Nolte, Ilja M and van der Vegt, Bert and Kootstra-Ros, Jenny E and Bakker, Stephan J L and Gansevoort, Ron T and Links, Thera P and Zandee, Wouter T and Eisenga, Michele F},
title = {Iron Status, Erythropoietin, and Cancer Incidence in the General Population},
journal = {European Journal of Clinical Investigation},
year = {2026},
volume = {56},
number = {5},
doi = {10.1111/eci.70218}
}
EUVIMED